|

Berzosertib Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1/2: 2

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • SCLC2
  • Lung Cancer2
  • Cancer2
  • HRD Cancer1
  • High Grade Neuroendocrine Cancers1

Bethesda, Maryland2 trials

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

National Institutes of Health Clinical Center

Phase 1/2
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.